Figure S2. FGF19 serum concentrations at 4 h versus C4 values at 6 h after the oral fat tolerance test (OFTT) in controls (N = 16). (DOCX 37 kb
Table S3. Natural logarithm transformed data for NAFLD stages analysis. (DOCX 12 kb
Table S2. Meta-regression analysis to assess the influence of continuous variables on the effect siz...
Table S1. Relative Risk of some factors in normal and NAFLD groups. Table S2. Variable scoring list ...
Figure S1. FGF19 serum concentrations at 2 h versus C4 values at 4 h after the oral fat tolerance te...
Table S1. Prevalence of comorbidities in overweight (Nâ=â14) and obese (12) NAFLD patients. In o...
Figure S2. The body weights, liver weights, serum and tissue triglyceride levels, alpha fetoprotein ...
Volcano plot [−log10 (p-value) vs. log2 (fold-change)] for the comparison between the baseline and f...
Electronic Supplementary Material: Figure S1. Histogram of MRI-derived liver fat content (%) values....
Odds ratios for NAFLD in different quartiles of TyG index or ALT in ALT <40 and âĽ40 U/L groups. Ta...
Figure S1. Diagnostic odds ratio (DOR) of CAP for steatosis in suspected NAFLD patients. Figure S2. ...
Figure S1. Male and female body composition. Figure S2. Serum cytokines and subcutaneous adipose tis...
Table S1. Stratified analysis of NAFLD and platelet count in different subgroup. (DOCX 27 kb
Table S1. The biomarker serum phospholipid fatty acids in wt% and quartiles (P25‚ 75), n = 49. Table...
Figure S1. The individual participant levels of iFGF23 (pg/mL), cFGF23 (RU/mL) and phosphate (mmol/...
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documen...
Table S3. Natural logarithm transformed data for NAFLD stages analysis. (DOCX 12 kb
Table S2. Meta-regression analysis to assess the influence of continuous variables on the effect siz...
Table S1. Relative Risk of some factors in normal and NAFLD groups. Table S2. Variable scoring list ...
Figure S1. FGF19 serum concentrations at 2 h versus C4 values at 4 h after the oral fat tolerance te...
Table S1. Prevalence of comorbidities in overweight (Nâ=â14) and obese (12) NAFLD patients. In o...
Figure S2. The body weights, liver weights, serum and tissue triglyceride levels, alpha fetoprotein ...
Volcano plot [−log10 (p-value) vs. log2 (fold-change)] for the comparison between the baseline and f...
Electronic Supplementary Material: Figure S1. Histogram of MRI-derived liver fat content (%) values....
Odds ratios for NAFLD in different quartiles of TyG index or ALT in ALT <40 and âĽ40 U/L groups. Ta...
Figure S1. Diagnostic odds ratio (DOR) of CAP for steatosis in suspected NAFLD patients. Figure S2. ...
Figure S1. Male and female body composition. Figure S2. Serum cytokines and subcutaneous adipose tis...
Table S1. Stratified analysis of NAFLD and platelet count in different subgroup. (DOCX 27 kb
Table S1. The biomarker serum phospholipid fatty acids in wt% and quartiles (P25‚ 75), n = 49. Table...
Figure S1. The individual participant levels of iFGF23 (pg/mL), cFGF23 (RU/mL) and phosphate (mmol/...
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documen...
Table S3. Natural logarithm transformed data for NAFLD stages analysis. (DOCX 12 kb
Table S2. Meta-regression analysis to assess the influence of continuous variables on the effect siz...
Table S1. Relative Risk of some factors in normal and NAFLD groups. Table S2. Variable scoring list ...
DOI
Add to ORKG